Search details
1.
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Hepatology
; 72(1): 58-71, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32115759
2.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLARĀ trials.
J Hepatol
; 73(1): 26-39, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32147362
3.
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Hepatology
; 70(6): 1913-1927, 2019 12.
Article
in English
| MEDLINE | ID: mdl-30993748
4.
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
Hepatology
; 70(5): 1521-1530, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31271665
5.
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Clin Gastroenterol Hepatol
; 17(12): 2552-2560.e10, 2019 11.
Article
in English
| MEDLINE | ID: mdl-30779990
6.
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.
Am J Gastroenterol
; 114(10): 1636-1641, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31464743
7.
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Hepatology
; 67(2): 549-559, 2018 02.
Article
in English
| MEDLINE | ID: mdl-28892558
8.
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
Circ Res
; 117(8): 731-41, 2015 Sep 25.
Article
in English
| MEDLINE | ID: mdl-26228031
9.
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
Diabetes Obes Metab
; 19(1): 98-107, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27619750
10.
Effect of evolocumab on cholesterol synthesis and absorption.
J Lipid Res
; 57(12): 2217-2224, 2016 12.
Article
in English
| MEDLINE | ID: mdl-27707817
11.
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
Cardiovasc Drugs Ther
; 30(3): 305-13, 2016 06.
Article
in English
| MEDLINE | ID: mdl-27240673
12.
Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis.
Therap Adv Gastroenterol
; 13: 1756284820923904, 2020.
Article
in English
| MEDLINE | ID: mdl-32523627
13.
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.
JCI Insight
; 3(2)2018 01 25.
Article
in English
| MEDLINE | ID: mdl-29367468
14.
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.
Lancet Diabetes Endocrinol
; 4(5): 403-10, 2016 05.
Article
in English
| MEDLINE | ID: mdl-26868195
Results
1 -
14
de 14
1
Next >
>>